SYS6055
/ CSPC Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2026
Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies
(clinicaltrials.gov)
- P1 | N=86 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China
New P1 trial • B Cell Lymphoma • Hematological Malignancies • Oncology
1 to 1
Of
1
Go to page
1